Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 20 March 2020

by | Mar 23, 2020

Significant biosimilar activities this week include

16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast cancer, metastatic breast cancer and metastatic gastric cancer.

19 Mar 20 | The Centre for Biosimilars reported on a pair of biosimilar bills which were introduced to the US Congress in the 2 weeks prior. These bills include a ‘shared savings’ model designed to encourage physicians to switch patients to biosimilars, and a program that would allow $0 co-pays for seniors prescribed biosimilars.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News